前沿速览035期| CAR-T治B淋 前沿览新知
01
新型CD19-1XX嵌合抗原受体（具有校准信号）在大B细胞淋巴瘤中的首次人体I期研究结果
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
第一作者：Park JH
J Clin Oncol (IF=42.1). 2025 Jan 30:JCO2402424.
全文网址：https://ascopubs.org/doi/10.1200/JCO-24-02424?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
年龄、种族和民族与儿童/成人B细胞恶性肿瘤患者接受CAR-T治疗可及性、反应及毒性的相关性：综述
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review
第一作者：Ghilardi G
J Immunother Cancer (IF=10.3). 2025 Jan 23;13(1):e009349.
全文网址：https://jitc.bmj.com/content/13/1/e009349.long
03
真实世界中Tafasitamab在复发/难治性弥漫大B细胞淋巴瘤患者接受CD19 CAR-T细胞治疗前的应用
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
第一作者：Epperla N
Biomark Res (IF=9.5). 2025 Jan 23;13(1):18.
全文网址：https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-024-00706-6
04
静脉-静脉时间对接受Axicabtagene Ciloleucel治疗的复发/难治性大B细胞淋巴瘤患者的影响
Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel
第一作者：Locke FL
Blood Adv (IF=7.4). 2025 Jan 30:bloodadvances.2024013656.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013656/535370/Impact-of-Vein-to-vein-Time-in-Patients-With-R-R
05
高级别B细胞淋巴瘤与其他大B细胞淋巴瘤在CAR-T挽救治疗后的预后对比：一项DESCAR-T LYSA研究
Outcome of high-grade B-cell lymphoma compared to other large B-cell lymphoma after CAR-T rescue. A DESCAR-T LYSA study
第一作者：Phina-Ziebin X
Blood Adv (IF=7.4). 2025 Jan 28:bloodadvances.2024014732.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024014732/535303/Outcome-of-high-grade-B-cell-lymphoma-compared-to
06
IL4I1基因敲除通过影响巨噬细胞改善复发/难治性弥漫大B细胞淋巴瘤中CD19 CAR-T联合PD-1抑制剂的疗效
Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma
第一作者：Zhang R
J Transl Med (IF=6.1). 2025 Jan 22;23(1):105.
全文网址：https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-06028-3
07
英国大B细胞淋巴瘤患者接受CAR-T治疗的可及性及预后与民族和社会经济贫困程度的关系
CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK
第一作者：Dragoi D
Br J Haematol (IF=5.1). 2025 Jan 16.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19997
08
CAR-HEMATOTOX及其简化版预测接受抗CD19 CAR-T细胞治疗的大B细胞淋巴瘤患者生存的前瞻性验证：来自CART-SIE研究的数据
Prospective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study
第一作者：Stella F
Transplant Cell Ther (IF=3.6). 2025 Jan 25:S2666-6367(25)00916-9.
全文网址：https://www.sciencedirect.com/science/article/pii/S2666636725009169?via%3Dihub
09
接受CAR-T细胞治疗的成年患者的长期认知结局
Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies
第一作者：Barata A
Transplant Cell Ther (IF=3.6). 2025 Jan 25:S2666-6367(25)00914-5.
全文网址：https://www.sciencedirect.com/science/article/abs/pii/S2666636725009145?via%3Dihub
10
低剂量西达本胺通过上调CD19的表达可促进B细胞非霍奇金淋巴瘤中CAR-T细胞的功能
Upregulation of CD19 by low-dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma
第一作者：Ni Y
Discov Oncol (IF=2.8). 2025 Jan 24;16(1):84.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11759751/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.2-5 valid until 2027.2
供稿与审核：临床开发与医学部